TruBridge (TBRG)
NASDAQ:TBRG
Top Page
TruBridge
(NASDAQ:TBRG)
Select Model
Select Model
Rating:55Neutral
Price Target:
$15.00
▲(2.46% Upside)
Action:ReiteratedDate:04/01/26
The score is mainly supported by improving financial performance (notably strong cash flow and margin/profitability recovery) and generally constructive earnings-call operational momentum. These positives are materially offset by very weak technicals (clear downtrend and negative momentum) and a demanding valuation (high P/E with no dividend support), with added near-term visibility risk from modest revenue growth and strategic-review uncertainty.
Positive Factors
Strong free cash flow generation
Sustained operating cash flow and a reported robust free cash flow position provide durable funding for debt reduction, working-capital needs, and selective reinvestment. Reliable cash generation supports deleveraging and gives management flexibility to execute strategic initiatives over the next several quarters.
Negative Factors
Modest top-line growth
Revenue growth remains tepid, limiting the company's ability to leverage fixed-cost improvements into durable earnings growth. Persistent low organic revenue expansion increases reliance on margin gains, pipeline conversion and larger deal wins to drive sustained profitability improvement over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow generation
Sustained operating cash flow and a reported robust free cash flow position provide durable funding for debt reduction, working-capital needs, and selective reinvestment. Reliable cash generation supports deleveraging and gives management flexibility to execute strategic initiatives over the next several quarters.
Read all positive factors
TruBridge (TBRG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$219.73M
Dividend YieldN/A
Average Volume (3M)110.38K
Price to Earnings (P/E)73.4
Beta (1Y)0.79
Revenue Growth3.75%
EPS GrowthN/A
CountryUS
Employees3,200
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.79
Shares Outstanding15,008,986
10 Day Avg. Volume98,314
30 Day Avg. Volume110,375
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)1.80
Price to Sales (P/S)0.92
P/FCF Ratio8.97
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue0.62
Enterprise Value/Gross Profit1.17
Enterprise Value/Ebitda3.72
Forecast
1Y Price Target
$20.25Price Target Upside38.32% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)2.3
Revenue Forecast (FY)$359.15M
TruBridge Business Overview & Revenue Model
Company Description
TruBridge, Inc. provides healthcare solutions and services for community hospitals, clinics, and other healthcare systems in the United States and internationally. The company operates in three segments: Revenue Cycle Management (RCM), Electronic ...
How the Company Makes Money
TruBridge makes money primarily by selling software and delivering technology-enabled services to healthcare provider organizations. Key revenue streams generally include: (1) recurring fees for software and hosted/managed solutions (e.g., subscri...
TruBridge Earnings Call Summary
Earnings Call Date:Mar 31, 2026
(Q4-2025)
| Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call emphasized meaningful operational and financial progress — margin expansion, stronger cash generation, debt reduction, a growing and higher-quality pipeline, AI pilots showing early benefits, and strengthened financing and controls. Key challenges highlighted included modest top-line growth, Patient Care revenue pressures from a product sunset and mix, retention impacts from global workforce transition, prior-period accounting adjustments that delayed filings, and uncertainty from an ongoing strategic review. Overall, management presented a confident operational improvement narrative but acknowledged short-term conversion and visibility risks.Positive Updates
Filed 10-K and Strengthened Financial Controls
10-K filed after identifying noncash out-of-period adjustments during first year-end audit with new external auditor; management emphasized strengthened reporting standards, controls and ongoing remediation of material weaknesses.
Negative Updates
Q4 Revenue Slight Decline and Product Sunset Impact
Q4 revenue was $87.2 million, a ~1% decrease versus prior year; Q4 Patient Care revenue $31.0 million, down 6.6% YoY. The sunset of the Centriq product reduced revenue by about $1 million in Q4 (normalizing would make revenue roughly flat).
Read all updates
Q4-2025 Updates
Positive
Negative
Filed 10-K and Strengthened Financial Controls
10-K filed after identifying noncash out-of-period adjustments during first year-end audit with new external auditor; management emphasized strengthened reporting standards, controls and ongoing remediation of material weaknesses.
Read all positive updates
Company Guidance
The company did not provide formal numeric guidance due to an ongoing strategic review, but said it expects modest revenue growth in 2026 and roughly 200 basis points of adjusted EBITDA margin improvement; supporting metrics from FY2025 include total revenue of $346.8 million (+1.4% YoY), adjusted EBITDA of $68.7 million (+23% YoY, +350 bps margin expansion in 2025 and >650 bps over two years), Q4 revenue of $87.2 million with Q4 adjusted EBITDA of $19.2 million (22% margin, +160 bps YoY), Q4 bookings of $19.8 million TCV and full-year bookings of $82.9 million TCV ($70.9 million ACV), free cash flow of $20 million (+$5 million YoY) and cash flow from operations of $37 million (+19%), cash of $24.9 million (vs. $12.3 million at year-end 2024), net debt of ~$139.8 million and net leverage of ~2x, a pipeline at a nine‑quarter high (up 53% since the start of Q3) with encoder pipeline +74%, recurring opportunities now >70% of pipeline (vs ~57% last summer) and a growing share of larger deals (>100 beds up to 30% of pipeline), which management cited as the basis for the modest growth and ~200 bps margin improvement outlook.TruBridge Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
52
Neutral
Cash Flow
74
Positive
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 346.84M | 342.65M | 339.44M | 326.65M | 280.63M |
| Gross Profit | 183.86M | 174.12M | 163.57M | 160.11M | 144.85M |
| EBITDA | 20.83M | 34.94M | -15.39M | 47.73M | 43.11M |
| Net Income | 4.35M | -20.44M | -45.79M | 15.87M | 18.43M |
Balance Sheet | |||||
| Total Assets | 402.53M | 394.43M | 431.78M | 430.96M | 383.35M |
| Cash, Cash Equivalents and Short-Term Investments | 24.85M | 12.32M | 3.85M | 6.95M | 11.43M |
| Total Debt | 4.73M | 174.81M | 203.29M | 147.24M | 106.46M |
| Total Liabilities | 224.57M | 225.74M | 247.80M | 199.25M | 160.78M |
| Stockholders Equity | 177.96M | 168.69M | 183.97M | 231.71M | 222.57M |
Cash Flow | |||||
| Free Cash Flow | 35.65M | 13.04M | -22.35M | 13.01M | 37.46M |
| Operating Cash Flow | 36.97M | 32.13M | 1.06M | 32.38M | 47.74M |
| Investing Cash Flow | -14.72M | 4.12M | -60.11M | -62.73M | -69.92M |
| Financing Cash Flow | -9.71M | -27.74M | 55.95M | 25.88M | 20.93M |
TruBridge Technical Analysis
Negative
14.64
Price Trends
18.53
Negative
20.10
Negative
20.52
Negative
Market Momentum
-1.34
Positive
30.73
Neutral
14.32
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TBRG, the sentiment is Negative. The current price of 14.64 is below the 20-day moving average (MA) of 16.38, below the 50-day MA of 18.53, and below the 200-day MA of 20.52, indicating a bearish trend. The MACD of -1.34 indicates Positive momentum. The RSI at 30.73 is Neutral, neither overbought nor oversold. The STOCH value of 14.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TBRG.
TruBridge Risk Analysis
TruBridge disclosed 44 risk factors in its most recent earnings report. TruBridge reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TruBridge Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $225.96M | 17.11 | 10.63% | 9.67% | 1.47% | 11.33% | |
64 Neutral | $117.83M | 44.33 | 4.22% | ― | 24.19% | ― | |
55 Neutral | $219.73M | 73.44 | 3.23% | ― | 3.75% | ― | |
54 Neutral | $238.13M | 127.44 | -45.47% | ― | 13.09% | -745.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $386.23M | 36.22 | 58.50% | 2.52% | -3.50% | -37.46% | |
45 Neutral | $93.45M | -0.47 | -30.28% | ― | 4.64% | -17.17% |
* Healthcare Sector Average
TBRG
TruBridge
14.64
-12.47
-46.00%
SLP
Simulations Plus
11.82
-12.95
-52.28%
SPOK
Spok Holdings
10.90
-4.29
-28.26%
OPRX
OptimizeRx
6.28
-2.05
-24.61%
NRC
National Research
16.98
5.23
44.45%
HCAT
Health Catalyst
1.27
-3.18
-71.46%
TruBridge Corporate Events
Business Operations and StrategyExecutive/Board Changes
TruBridge enters cooperation pact and refreshes board leadership
Positive
Jan 8, 2026
On January 7, 2026, TruBridge entered into a cooperation agreement with its largest shareholder, Pinetree Capital and L6 Holdings, under which the company will expand its board to appoint Pinetree president Damien Leonard as an independent directo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.